…
Metro Inc., through its subsidiaries, operates as a retailer, franchisor, distributor, and manufacturer in the food and pharmaceutical sectors in Canada. The company operates supermarkets, discount stores, neighbourhood stores, specialized stores, and pharmacies that provide fresh and grocery products, baked goods, prepared food products, meats, dairy products, fruits and vegetables, frozen food products, bakery products, prepared meals, delicatessen items, fruits and vegetables, frozen products and pastries. It also manufactures ready-to-eat meals, salads, dips, pastries, pies, breads, and cakes; generic drugs under Pro Doc trademark; and provides online grocery shopping services. In addition, the company offers its private label food products under Irresistibles, Selection, Harvest Best, Lucky Koi, Life Smart, Adonis, Phoenicia, and Premiere Moisson brands; and private label drug products comprising beauty and cosmetic products, over-the-counter medications, health & beauty, cosmetics, and baby categories sold under the Personnelle brand name. It operates a network of food stores under various banners, including Metro, Metro Plus, Adonis, Super C, Marché Richelieu, Marché Ami, Première Moisson, Les 5 Saisons, and Food Basics, as well as pharmacies primarily under the PJC Jean Coutu, PJC Santé, PJC Santé Beauté, Brunet, Brunet Plus, Brunet Clinique, Clini Plus, Metro Pharmacy, and Food Basics Pharmacy banners. The company was founded in 1947 and is headquartered in Montreal, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Metro Inc. operates a network of supermarkets and pharmacies in Canada, primarily serving Quebec and Ontario under banners including Metro and Jean Coutu. Long-term growth drivers include steady demand for food and health products, expansion of private-label and e-commerce channels, and aging demographics that may support pharmacy sales; investors may find it attractive because it appears positioned to generate stable cash flows through scale and an integrated retail model.
The company faces material risk from intense competition from national retailers and discounters that could pressure margins and market share.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 1320.20M | 1250.10M | 1321.80M | 1153.60M | 1120.70M |
| Minority interest | -2.50M | -2.90M | -4.00M | -3.40M | -2.70M |
| Net income | 1017.00M | 928.80M | 1014.80M | 846.10M | 823.00M |
| Selling general administrative | - | - | - | 1389.50M | 1389.50M |
| Gross profit | 3775.90M | 4179.30M | 4082.20M | 3783.30M | 3654.80M |
| Reconciled depreciation | 594.40M | 570.40M | 525.00M | 503.30M | 478.30M |
| Ebit | 1484.30M | 1416.60M | 1471.80M | 1331.20M | 1266.50M |
| Ebitda | 2078.70M | 1987.00M | 1997.00M | 1834.50M | 1744.80M |
| Depreciation and amortization | 594.40M | 570.40M | 525.20M | 503.30M | 478.30M |
| Operating income | 1463.90M | 1409.80M | 1440.20M | 1331.20M | 1266.50M |
| Other operating expenses | 20518.30M | 19810.10M | 19284.40M | 17572.90M | 17028.80M |
| Interest expense | 165.60M | 167.90M | 151.40M | 132.80M | 145.80M |
| Tax provision | 300.70M | 318.40M | 303.00M | 304.10M | 295.00M |
| Interest income | 150.90M | 22.40M | 29.10M | 117.60M | 128.90M |
| Net interest income | -143.80M | -145.70M | -122.60M | -117.60M | -133.50M |
| Income tax expense | 300.70M | 318.40M | 303.00M | 304.10M | 295.00M |
| Total revenue | 22006.70M | 21219.90M | 20724.60M | 18888.90M | 18283.00M |
| Total operating expenses | 2881.90M | 2769.50M | 2642.00M | 2467.30M | 2400.60M |
| Cost of revenue | 18230.80M | 17040.60M | 16642.40M | 15105.60M | 14628.20M |
| Total other income expense net | -168.20M | -159.70M | -118.40M | -177.60M | -145.80M |
| Net income from continuing ops | 1019.50M | 931.70M | 1018.80M | 849.50M | 825.70M |
| Net income applicable to common shares | 1017.00M | 928.80M | 1014.80M | 846.10M | 823.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 14539.40M | 14140.60M | 13865.30M | 13401.30M | 13592.10M |
| Intangible assets | 2661.20M | 2698.90M | 2733.00M | 2739.00M | 2854.70M |
| Other current assets | 79.40M | 73.20M | - | 54.10M | 46.60M |
| Total liab | 7494.30M | 7101.70M | 7049.00M | 6782.90M | 7179.30M |
| Total stockholder equity | 7026.70M | 7021.70M | 6801.20M | 6604.50M | 6399.90M |
| Other current liab | - | - | - | 44.10M | 55.00M |
| Common stock | 1544.70M | 1575.50M | - | 1649.30M | 1674.30M |
| Capital stock | 1544.70M | 1575.50M | 1601.10M | 1649.30M | 1674.30M |
| Retained earnings | 5481.60M | 5441.40M | 5195.60M | 4947.20M | 4721.90M |
| Other liab | - | - | - | 1003.20M | 1005.40M |
| Good will | 3317.10M | 3314.20M | 3307.40M | 3301.20M | 3301.20M |
| Other assets | 438.30M | - | - | 725.00M | 774.90M |
| Cash | 67.30M | 29.40M | 29.50M | 13.40M | 445.80M |
| Cash and equivalents | 67.30M | - | - | 13.40M | 445.80M |
| Total current liabilities | 2053.80M | 2285.60M | 1960.80M | 1952.50M | 2198.20M |
| Current deferred revenue | 44.60M | 42.70M | - | 38.50M | 35.90M |
| Net debt | 4534.70M | 4281.10M | 2636.10M | 4108.40M | 4118.20M |
| Short term debt | 293.10M | 580.80M | - | 294.60M | 588.30M |
| Short long term debt | 17.20M | 317.20M | 19.30M | 18.30M | 318.60M |
| Short long term debt total | 4602.00M | 4310.50M | - | 4121.80M | 4564.00M |
| Other stockholder equity | 1.80M | 5.90M | - | 7.10M | 3.70M |
| Property plant equipment | 5085.60M | - | - | 4452.80M | 4194.50M |
| Total current assets | 2661.00M | 2474.00M | 2403.60M | 2183.30M | 2466.80M |
| Long term investments | - | - | - | 9.40M | - |
| Net tangible assets | - | - | - | 564.30M | 244.00M |
| Net receivables | 910.00M | 863.10M | 728.30M | 784.70M | 805.40M |
| Long term debt | 2938.10M | 2357.10M | 2646.30M | 2324.50M | 2318.20M |
| Inventory | 1604.30M | 1508.30M | 1451.00M | 1331.10M | 1169.00M |
| Accounts payable | 1661.80M | 1645.90M | 1619.40M | 1575.30M | 1546.50M |
| Accumulated other comprehensive income | -1.40M | -1.10M | - | 0.90M | - |
| Treasury stock | - | - | - | - | -20.50M |
| Non currrent assets other | 404.10M | 712.40M | 85.30M | 670.80M | 717.80M |
| Non current assets total | 11878.40M | 11666.60M | 11461.70M | 11218.00M | 11125.30M |
| Capital lease obligations | 1646.70M | 1636.20M | 1658.70M | 1779.00M | 1927.20M |
| Long term debt total | 4308.90M | - | - | 3827.20M | 3975.70M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -408.60M | -456.40M | -572.50M | -477.80M | -1.10M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -424.00M | -471.50M | -572.50M | -477.80M | -471.60M |
| Net borrowings | -5.20M | -276.70M | 43.60M | -554.30M | -263.30M |
| Total cash from financing activities | -1151.90M | -1091.70M | -974.90M | -1416.00M | -1107.40M |
| Change to operating activities | - | - | - | -115.20M | 162.20M |
| Net income | 1320.20M | 928.80M | 1014.80M | 1153.60M | 1120.70M |
| Change in cash | 37.90M | -0.10M | 16.10M | -432.40M | 4.30M |
| Begin period cash flow | 29.40M | 29.50M | 13.40M | 445.80M | 441.50M |
| End period cash flow | 67.30M | 29.40M | 29.50M | 13.40M | 445.80M |
| Total cash from operating activities | 1613.80M | 1563.10M | 1563.50M | 1461.40M | 1583.30M |
| Issuance of capital stock | 24.10M | 18.90M | 7.80M | 21.00M | 12.60M |
| Depreciation | 594.40M | 570.40M | 525.20M | 503.30M | 478.30M |
| Other cashflows from investing activities | 29.50M | 94.10M | 107.40M | 96.00M | 106.40M |
| Dividends paid | -316.80M | -294.60M | 275.00M | 257.90M | 240.10M |
| Sale purchase of stock | -801.30M | -485.70M | -593.60M | -470.00M | -456.30M |
| Other cashflows from financing activities | -334.40M | -321.40M | 343.20M | 175.70M | -138.70M |
| Change to netincome | - | - | - | 227.20M | 118.10M |
| Capital expenditures | 452.50M | 499.00M | 679.90M | 621.10M | 599.30M |
| Change in working capital | -126.70M | -54.30M | -125.50M | -115.20M | 162.20M |
| Stock based compensation | 13.80M | 13.10M | 12.00M | 8.60M | 10.60M |
| Other non cash items | -187.90M | 118.20M | 122.60M | -88.90M | -188.50M |
| Free cash flow | 1161.30M | 1064.10M | 883.60M | 840.30M | 984.00M |
Sector: Consumer Defensive Industry: Grocery Stores
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRU Metro Inc. |
1.98 2.02% |
100.16 | 20.41 | 17.95 | 0.89 | 2.80 | 1.10 | 11.78 |
| L Loblaw Companies Limited |
1.33 1.92% |
70.65 | 29.49 | 23.81 | 1.14 | 6.56 | 1.36 | 12.13 |
| WN George Weston Limited |
2.61 2.40% |
111.36 | 36.80 | 19.84 | 0.57 | 8.15 | 0.86 | 7.75 |
| WN-PA George Weston Prf |
0.20 0.79% |
25.50 | 6.97 | - | 0.23 | - | - | - |
| WN-PE George Weston 4.75 Ser V Prf |
0.20 0.95% |
21.24 | 5.84 | - | 0.22 | - | - | - |
Metro Inc., through its subsidiaries, operates as a retailer, franchisor, distributor, and manufacturer in the food and pharmaceutical sectors in Canada. The company operates supermarkets, discount stores, neighbourhood stores, specialized stores, and pharmacies that provide fresh and grocery products, baked goods, prepared food products, meats, dairy products, fruits and vegetables, frozen food products, bakery products, prepared meals, delicatessen items, fruits and vegetables, frozen products and pastries. It also manufactures ready-to-eat meals, salads, dips, pastries, pies, breads, and cakes; generic drugs under Pro Doc trademark; and provides online grocery shopping services. In addition, the company offers its private label food products under Irresistibles, Selection, Harvest Best, Lucky Koi, Life Smart, Adonis, Phoenicia, and Premiere Moisson brands; and private label drug products comprising beauty and cosmetic products, over-the-counter medications, health & beauty, cosmetics, and baby categories sold under the Personnelle brand name. It operates a network of food stores under various banners, including Metro, Metro Plus, Adonis, Super C, Marché Richelieu, Marché Ami, Première Moisson, Les 5 Saisons, and Food Basics, as well as pharmacies primarily under the PJC Jean Coutu, PJC Santé, PJC Santé Beauté, Brunet, Brunet Plus, Brunet Clinique, Clini Plus, Metro Pharmacy, and Food Basics Pharmacy banners. The company was founded in 1947 and is headquartered in Montreal, Canada.
11011 Maurice-Duplessis Boulevard, Montreal, QC, Canada, H1C 1V6
514 643 1000
99000
| Name | Title | Year Born |
|---|---|---|
| Mr. Francois Thibault | Exec. VP, CFO & Treasurer | NA |
| Mr. Eric Richer La Fleche | Pres, CEO & Non-Independent Director | 1962 |
| Mr. Marc Giroux | Exec. VP & COO ? Food | NA |
| Mr. Carmen Fortino | Exec. VP of National Supply Chain & Procurement | 1959 |
| Mr. Sam Bernier | VP of Technology Infrastructure | NA |
| Mr. Frederic Legault | VP & Chief Information Officer | NA |
| Mr. Simon Rivet | VP, Gen. Counsel & Corp. Sec. | NA |
| Ms. Marie-Claude Bacon | VP of Public Affairs & Communications | NA |
| Mr. Alain Tadros | VP of Marketing | NA |
| Ms. Geneviève Bich | VP of HR | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.